Eduard R. Felder
Nerviano, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids.
Journal: Chirality
Published: May 14, 2022
Identification of unprecedented ATP-competitive choline kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: April 27, 2021
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Journal: Journal of medicinal chemistry
Published: August 20, 2019
Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-competitive Inhibitors.
Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-competitive Inhibitors.
Journal: Acta chimica Slovenica
Published: June 01, 2019
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.
Journal: ACS medicinal chemistry letters
Published: November 22, 2018
The target landscape of clinical kinase drugs.
Journal: Science (New York, N.Y.)
Published: April 13, 2017
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Journal: Journal of medicinal chemistry
Published: March 23, 2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Journal: Molecular cancer therapeutics
Published: September 11, 2015
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Journal: Journal of medicinal chemistry
Published: July 30, 2015
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Journal: Bioorganic & medicinal chemistry
Published: January 12, 2015
Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors.
Journal: Journal of medicinal chemistry
Published: December 05, 2014
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Journal: ChemMedChem
Published: September 30, 2014
Last Updated: 09/26/2026